Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

By I. Jacobson, S. Gordon, Kris V. Kowdley, Eric M. Yoshida, M. Rodríguez-Torres, M. Sulkowski, M. Shiffman, E. Lawitz, G. Everson, M. Bennett and 13 more. New England Journal of Medicine, 2013

1,172 citations recorded by the source corpus.

Subfields: Emergency Medicine, Genetics, Hepatology

View Paper: https://www.semanticscholar.org/paper/22e8bafa516f1f0a449da3468e796ecf3d1838a6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Oliver George Pybus
2. D. Rabosky
3. L. Garamszegi

In Hepatology

1. Christoph Sarrazin
2. A. Aghemo
3. G. Dusheiko
4. M. Puoti
5. X. Forns
6. J. Pawlotsky

Citations in the corpus

• Sofosbuvir and ribavirin in HCV genotypes 2 and 3. (2014, neutral): “No response†† 18 (21) 10 (14) 4 (36) 41 (16)”
• EASL Recommendations on Treatment of Hepatitis C 2016. (2017, methodology): “When comparing 12 and 16 weeks of therapy in the FUSION trial [31], SVR was achieved in 82% (32/39) and 89% (31/35) of cases, respectively, 60% (6/10) and 78% (7/9) in patients with cirrhosis, respectively.”
• Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (2019, methodology): “(286) The use of sofosbuvir plus ribavirin is further supported by clinical trial data involving adolescents(287) and adults with genotype 2 or 3 infection.(288-291) At the time of manuscript preparation, sofosbuvir (plus ribavirin) remained the only FDA-approved DAA for children 3-11 years with gen”
• All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study (2015, methodology): “The all-oral combination of SOF plus RBV requires 24 weeks of treatment because 12- and 16-week treatment durations were associated with lower response rates (30%-61% and 62%, respectively) in genotype 3– infected patients.(7,13,14) With 24-week treatment, lower response rates were observed in genot”
• Global Distribution and Prevalence of Hepatitis C Virus Genotypes (2014, background): “Genotype 3, however, which accounts for 30% of global infections, is not susceptible to the first generation of DAA protease inhibitors, and also appears less susceptible than other genotypes to sofosbuvir, the most advanced second-generation DAA therapy to date.(33,34) Ultimately, should DAA therap”
• EASL Recommendations on Treatment of Hepatitis C 2018. (2018, methodology): “When comparing 12 and 16 weeks of therapy in the FUSION trial [31], SVR was achieved in 82% (32/39) and 89% (31/35) of cases, respectively, 60% (6/10) and 78% (7/9) in patients with cirrhosis, respectively.”
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. (2014, neutral): “Insomnia 17 (8) 45 (21) 26 (12) 47 (22)”
• EASL Recommendations on Treatment of Hepatitis C 2015. (2015, methodology): “When comparing 12 and 16 weeks of therapy in the FUSION trial [46], SVR was achieved in 30% (19/64) and 62% (39/63) of cases, respectively, 19% (5/26) and 61% (14/23) in patients with cirrhosis, respectively.”